Pancreatic cancer gene map could lead to smarter treatments

NCT ID NCT02750657

Completed Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the genes in tumors from 332 people with advanced pancreatic cancer. The goal was to see if genetic changes could help doctors choose better treatments. Researchers compared genetic information with how patients responded to their first chemotherapy. This is a completed study that may guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors choose more effective treatments for pancreatic cancer patients based on their tumor's genetic profile.
What could go wrong: This is an observational study, not a treatment trial. It may not directly improve outcomes, and genetic testing may not always predict treatment response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, PANCREATIC DUCTAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, PANCREATIC DUCTAL

Contacts and locations

Locations

Centre Hospitalier de l'Universite de Montreal (CHUM)

Montreal, Quebec, H2X 3E4, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L2V7, Canada
McGill University Health Centre

Montreal, Quebec, H4A3J1, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.